Core Insights - QcX Gold Corp. is set to conduct a large-scale, high-resolution airborne magnetic survey at its Batchawana Project in Ontario, with work commencing in November 2025 [1][3]. Project Overview - The Batchawana Project is adjacent to Sterling Metals Corp.'s Soo Copper Project, which recently reported significant copper discoveries, including intervals of 262.5 m at 1.05% CuEq, 68.3 m at 3.25% CuEq, and 9.3 m at 19.8% CuEq [2]. - QcX shares a 6.6 km boundary with the discovery area, positioning the company in a promising emerging copper district in Canada [2]. Survey Details - The magnetic survey will utilize 75-metre line spacing to gather detailed magnetic data, aiding in the identification of structural features, stratigraphy, and potential mineralized centers [3]. - The new geophysical data will be integrated with historical datasets to create high-priority targets for ground-based exploration in 2026 [3]. Geological Context - The Batchawana Project is situated within the Precambrian Batchawana Greenstone Belt, part of the Mid-Continent Rift, known for hosting large porphyry-style copper systems [4]. - The property is located along the strike of the historically productive Tribag Mine, which was mined for copper, molybdenum, silver, and gold [5]. Strategic Alignment - The geological features of the Batchawana Project show continuity with Sterling's mineralized corridor, with historic soil anomalies and untested geophysical conductors that have not been systematically explored using modern techniques [6]. Future Plans - Following the interpretation of the magnetic survey results, QcX plans to initiate a property-wide prospecting and ground-truthing program in 2026, focusing on delineating copper-molybdenum-silver-gold porphyry targets [7].

Core Viewpoint - CleanTech Vanadium Mining Corp. has expanded its royalty agreement with Oracle Commodity Holding to include newly acquired fluorspar properties in Illinois, enhancing its mineral rights portfolio and potential revenue streams [1][2]. Group 1: Royalty Agreement Details - The Third Amending Agreement includes 37 mineral-rights parcels totaling 1,605 acres in Pope and Hardin Counties, Illinois [2]. - Oracle Commodity Holding is entitled to a 2% net smelter return royalty on minerals produced and sold from the properties, with a minimum of US$6 per tonne of minerals sold [3]. - Oracle Commodity Holding will pay USF 20% of US$68,700 to acquire the royalty on the new Illinois fluorspar properties [5]. Group 2: Financial Considerations - Oracle Commodity Holding will make non-refundable cash payments equal to 20% of the cash consideration that USF has paid or will pay to vendors for acquiring the properties, contingent upon actual cash payments made by USF [4]. Group 3: Company Background - CleanTech is focused on critical mineral resources in the USA, controlling over 17,550 acres of mineral rights with historic fluorspar resources in the Illinois-Kentucky Fluorspar District [7].

Core Insights - Phio Pharmaceuticals Corp. is set to present its INTASYL siRNA drug technology at the Advanced Therapies USA 2025 Congress, highlighting its potential in cancer treatment [1][2] - The INTASYL technology aims to down-regulate gene expression, with a specific focus on the PH-762 compound for treating cutaneous carcinomas [2][3] Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company that specializes in immuno-oncology therapeutics using its proprietary INTASYL® gene silencing technology [3] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [3] Presentation Details - The podium presentation titled "INTASYL® Synthesized siRNA Drug Technology" will take place on November 18, 2025, at 1:15 PM EDT in the Innovation Showcase at the Pennsylvania Convention Center [2] - Melissa Maxwell, M.S., will be the presenting author, emphasizing the significance of INTASYL technology in enhancing cancer treatment [2]

Core Insights - SOL Strategies Inc. has been selected as a staking provider for the VanEck Solana ETF, utilizing its Orangefin validator [1][3] - This partnership underscores SOL Strategies' commitment to integrating traditional finance with decentralized infrastructure [2][3] - The selection highlights the institutional interest in compliant and high-performance staking solutions within the Solana ecosystem [3] Company Overview - SOL Strategies Inc. is a Canadian investment company focused on blockchain innovation, particularly within the Solana ecosystem [4] - The company operates revenue-generating validator services and holds a significant Solana treasury [1][4] - SOL Strategies has established a track record of institutional partnerships, including collaborations with Tetra Trust and other financial institutions [3] Financial Metrics - SOL Strategies currently secures over CAD$610 million in staked assets through its certified validators [3]

Core Insights - Artificial Intelligence Technology Solutions, Inc. (AITX) has secured an order for ten ROSA™ units and ten SARA™ licenses for deployment in a major U.S. sports venue, aimed at enhancing security and monitoring capabilities [1][3][5] Company Overview - AITX, through its subsidiary Robotic Assistance Devices, Inc. (RAD), is a leader in AI-driven security solutions, targeting the $50 billion U.S. security and guarding services industry [7] - RAD's solutions can provide cost savings of 35%-80% compared to traditional manned security services [7] Product Details - The ROSA units are compact, portable security solutions that can be installed in about 15 minutes, featuring AI-driven analytics for human, firearm, and vehicle detection, as well as license plate recognition [6] - SARA, the AI platform integrated with ROSA, enhances event detection and response, allowing security teams to focus on higher-value tasks while maintaining consistent coverage [5][6] Market Position - RAD has a prospective sales pipeline that includes over 35 Fortune 500 companies, indicating strong potential for recurring revenue through reorders [10] - The company is actively exploring additional RAD offerings for broader facility coverage, including ROAMEO™ and RIO™ units [3][10] Leadership and Expertise - The leadership team at RAD includes experienced professionals from the security services industry, enhancing the company's ability to deliver innovative solutions [9]

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177687&wire=5&utm_campaign=1or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Cann ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged securities fraud affecting shareholders between August 6, 2024, and August 4, 2025 [2] Group 1: Lawsuit Details - The lawsuit claims that the company made false statements and concealed the poor demand for its new product, Inspire V, which was launched unsuccessfully due to significant surplus inventory and reluctance from providers to adopt the new treatment [3] - The complaint highlights that the company failed to complete essential tasks for a successful launch, including training and onboarding for treatment center customers, setting up IT systems, updating insurer claims software, and ensuring Medicare reimbursement was in place [3] Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Group 3: Legal Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States [5]

Core Insights - MBody AI has secured over 98% shareholder approval for its merger with Check-Cap, positioning it as a leading player in the embodied AI sector on Nasdaq [2][9] - The merger is expected to close in the coming weeks, subject to customary conditions, marking a significant transformation for Check-Cap into a dedicated embodied AI company [2][9] Industry Trends - U.S. enterprises are rapidly adopting full-facility embodied AI systems, driven by the need for significant cost savings and addressing labor volatility and compliance pressures [4] - Automation is becoming a strategic necessity rather than an experimental endeavor, indicating a shift in how businesses view robotics and AI integration [4] Company Overview - MBody AI operates the MBody AI Orchestrator™, a hardware-agnostic platform that integrates various robotic and sensor systems, facilitating automation across multiple industries [5][6] - The platform allows for reduced risk, fast deployment, and measurable ROI in sectors such as hospitality, healthcare, logistics, retail, and data centers [6] Leadership Insights - David Lontini, Chairman of Check-Cap, emphasized the significance of the 98% approval rate, highlighting the merger's potential to create a unique embodied AI company at a critical time for enterprise adoption [7] - John Fowler, CEO of MBody AI, noted that the demand for a unified orchestration platform is growing, as customers seek comprehensive solutions rather than fragmented hardware [7] Company Positioning - MBody AI is recognized as a global leader in embodied AI, aiming to create an autonomous workforce and already serving Fortune 500 companies [8] - The merger with Check-Cap will enhance MBody AI's market presence and capabilities in the embodied AI landscape [9]

Core Insights - The targeted radiotherapy cancer market is experiencing significant growth, particularly in the radioligand therapy (RLT) segment, driven by technological advancements and increased investment [4][5] - Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is focusing on developing next-generation targeted radiotherapies, with a strong emphasis on its lead program, ATNM-400, which targets multiple cancers [6][7] Company Overview - Actinium Pharmaceuticals is a pioneer in differentiated, targeted radiotherapies, holding approximately 250 issued and pending patents globally [1] - The company is developing ATNM-400, a first-in-class alpha-emitter targeted radiotherapy candidate, with preclinical data showing promise in prostate cancer, non-small cell lung cancer, and breast cancer [6][7] Market Dynamics - Novartis, a key player in the RLT market, is expanding its portfolio and has projected the RLT market could be valued between $25 billion and $30 billion [5] - Novartis's Pluvicto, approved for prostate cancer, generated sales of approximately $1.39 billion in 2024 and is expected to reach around $4.3 billion by 2030 [6] Competitive Landscape - Actinium's ATNM-400 is positioned to address unmet needs in the metastatic prostate cancer treatment landscape, particularly for patients who do not respond to existing therapies like Pluvicto [9][10] - The company believes that ATNM-400 can target a significant subset of the mCRPC patient population, especially those who have progressed on second-generation ARPIs or have not responded to PSMA-targeted therapies [11] Research and Development - Actinium is evaluating the potential of Actimab-A, which targets CD33 in acute myeloid leukemia and myelodysplastic syndromes, and Iomab-ACT, aimed at improving access to cellular therapies [7][8] - The company has reported superior tumor control and improved overall survival in preclinical studies for ATNM-400 compared to existing therapies [8][10] Collaborations and Innovations - Lila Biologics has announced a collaboration with Eli Lilly to develop novel radioligand therapies for solid tumors, showcasing the trend of partnerships in the biotech sector [12][13] - AdvanCell is expanding its collaboration with Eli Lilly to develop targeted alpha therapies, indicating a growing interest in innovative cancer treatments [14][15][16]

Core Insights - Forge Resources Corp. announced high-grade gold assay results of 105 g/t Au over a core length of 1.25 m from drill hole ALT-25-012 at the Alotta Project, indicating strong gold potential in the Payoff Zone [1][4][6] Company Overview - Forge Resources Corp. is a Canadian junior exploration company focused on the Alotta project, which consists of 230 mineral claims covering approximately 4,723 hectares in the Yukon Territory [26] - The Alotta project is located 50 km southeast of the Casino porphyry deposit, one of the largest undeveloped gold-copper porphyry projects globally [24] Drilling Program - The Phase 2 diamond drill program involved 1,262.75 m of drilling across four drill holes, with results from drill hole ALT-25-012 being highlighted [11][16] - The drilling confirmed widespread gold-bearing sulphide mineralization and quartz veining across a 500-meter strike length, reinforcing the zone's potential within a large geophysical anomaly [6][16] Assay Results - The assay results from drill hole ALT-25-012 showed 105 g/t Au over 1.25 m, with additional assays pending for silver, copper, and molybdenum [13][4] - Previous drill hole results included 0.46 g/t Au over 211.65 m and 0.45 g/t Au over 53.22 m, indicating consistent gold mineralization across the Payoff Zone [16] Exploration Strategy - The company plans to prioritize several large 'bull's-eye' targets defined by coincident copper, gold, and molybdenum soil anomalies and supporting geophysical signatures as exploration advances [4] - Visible gold within quartz veining has been observed, underscoring the robustness of the mineralized corridor [4][6] Upcoming Events - Forge Resources will participate in the Yukon Geoscience Forum from November 16 to 19, showcasing select drill core from the Alotta property [19]